Jaifar Alomairi

Jaifar Alomairi

Auto-generated profile, based on publicly available information

Jaifar Alomairi

Department of Medicine, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
AAAlsalt Al-Busaidi
Alsalt Al-Busaidi
OAOmer Alabri
Omer Alabri
JAJaifar Alomairi
Jaifar Alomairi
AEAhmed ElSharaawy
Ahmed ElSharaawy
ALAbdullah Al Lawati
Abdullah Al Lawati
SDSrijit Das
Srijit Das
: Gut microbiota refers to the population of trillions of microorganisms present in the human intestine. The gut microbiota in the gastrointestinal system is important for an individual’s good health and well-being. The possibility of an intrauterine colonization of the placenta further suggests that the fetal environment before birth may also affect early microbiome development. Various factors influence the gut microbiota. Dysbiosis of microbiota may be associated with various diseases. Insulin regulates blood glucose levels, and disruption of the insulin signaling pathway results in insulin resistance. Insulin resistance or hyperinsulinemia is a pathological state in which the insulin-responsive cells have a diminished response to the hormone compared to normal physiological responses, resulting in reduced glucose uptake by the tissue cells. Insulin resistance is an important cause of type 2 diabetes mellitus. While there are various factors responsible for the etiology of insulin resistance, dysbiosis of gut microbiota may be an important contributing cause for metabolic disturbances. We discuss the mechanisms in skeletal muscles, adipose tissue, liver, and intestine by which insulin resistance can occur due to gut microbiota's metabolites. A better understanding of gut microbiota may help in the effective treatment of type 2 diabetes mellitus and metabolic syndrome.

17 August 2023 in EXCLI Journal
Verified
Journal Article
Open access
AAAlsalt Al-Busaidi
Alsalt Al-Busaidi
JAJaifar Alomairi
Jaifar Alomairi
OAOmer Alabri
Omer Alabri
EAEissa Alwheibi
Eissa Alwheibi
AAAlazhar Almaghadari
Alazhar Almaghadari
POP. Ronan O'COnnell
P. Ronan O'COnnell
Dieulafoy’s lesion is a life-threatening and rare vascular malformation of the submucosal vessel that protrudes to the mucosa of the gastrointestinal tract. The vessel is abnormally dilated, and if it ruptures, it can cause severe acute gastrointestinal bleeding. We report an upper GI bleeding case due to Dieulafoy’s lesion in the gastric fundus of the stomach in a 76-year-old female. The patient presented with hematemesis and melena associated with anemia. An esophagogastroduodenoscopy (OGD) was performed which showed profuse pulsatile bleeding at the gastric fundus. Following that, gastrotomy confirmed the diagnosis of Dieulafoy’s lesion. Endoscopy is the main diagnostic and therapeutic tool for Dieulafoy’s lesion. Endoscopic treatment includes injective, ablative and mechanical therapies. The majority of cases are treated endoscopically, while in some cases, surgical intervention is deemed to be necessary as it is currently the only definitive treatment of Dieulafoy’s lesion.